KRAS, one of can­cer’s tough­est tar­gets, sees a surge of new ther­a­pies try­ing to lim­it side ef­fects: #AACR23

OR­LAN­DO – Two years af­ter Am­gen won ap­proval for a drug go­ing af­ter one of can­cer’s most frus­trat­ing ge­net­ic tar­gets, re­searchers be­lieve they’re fi­nal­ly be­gin­ning …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.